Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Gino Santini
AddedMar 31, 2024
UpdatedMay 31, 2026
Gino Santini

Gino Santini

Board Member, Collegium Pharmaceutical

LinkedIn

Gino Santini's Career

Collegium Pharmaceutical
Collegium Pharmaceutical

Stoughton, MA, US

Board Member· Board
Intercept Pharmaceuticals
Intercept Pharmaceuticals

New York City, NY, US

Board Member· Board
Artax Biopharma
Artax Biopharma

Cambridge, MA, US

Board Member· Board
Intarcia Therapeutics
Intarcia Therapeutics

Hayward, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Gino Santini's Career

Collegium Pharmaceutical
Collegium Pharmaceutical
Public$309.2M2072002Stoughton, MA, US
Board Member· Board

Leadership at Collegium Pharmaceutical

Michael HeffernanMichael HeffernanBoard Member
Neil McFarlaneNeil McFarlaneBoard Member
Joe CiaffoniJoe CiaffoniBoard Member
Dr John Gordon FreundDr John Gordon FreundBoard Member
Intercept Pharmaceuticals
Intercept Pharmaceuticals
Public$970M3412002New York City, NY, US
Board Member· Board

Leadership at Intercept Pharmaceuticals

Paolo FundaròPaolo FundaròBoard Member
Mark PruzanskiMark PruzanskiBoard Member
Dan BradburyDan BradburyBoard Member
Luca BenattiLuca BenattiBoard Member
Jerome DursoJerome DursoCEO

Similar to Intercept Pharmaceuticals

Mirum PharmaceuticalsMirum PharmaceuticalsFoster City, CA, USPharmaceuticalsest. 2018Mirum PharmaceuticalsFoster City, CA, US · est. 2018

Mirum Pharmaceuticals, Inc.: A US-based biopharmaceutical company specializing in cholestatic liver disease therapies.

Public · $497M196
Gilead SciencesGilead SciencesFoster City, CA, USPharmaceuticals, Therapiesest. 1987Gilead SciencesFoster City, CA, US · est. 1987

Gilead Sciences: An American biopharmaceutical firm innovating therapies for critical diseases.

Public · $2B17k
PTC TherapeuticsPTC TherapeuticsSouth Plainfield, NJ, USPharmaceuticalsest. 1998PTC TherapeuticsSouth Plainfield, NJ, US · est. 1998

PTC Therapeutics, Inc.: A US-based pharmaceutical company specializing in oral, small-molecule drugs for genetic disorders, oncology, and infectious diseases.

Public · $1.6B1.4k
Bristol Myers SquibbBristol Myers SquibbNew York City, NY, USPharmaceuticalsest. 1887Bristol Myers SquibbNew York City, NY, US · est. 1887

Leading American pharmaceutical company specializing in research and development.

Public · $10.6B34.3k
Artax Biopharma
Artax Biopharma
Public$67.8M142013Cambridge, MA, US
Board Member· Board

Leadership at Artax Biopharma

Javier GarciaJavier GarciaBoard Member
Damia TormoDamia TormoBoard Member
Robert ArmstrongRobert ArmstrongBoard Member
Joseph LobackiJoseph LobackiCEO
Andre HoekemaAndre HoekemaBoard Member
Casper BreumCasper BreumBoard Member

Similar to Artax Biopharma

Artielle ImmunoTherapeuticsArtielle ImmunoTherapeuticsSan Mateo, CA, USDrug Developmentest. 2004Artielle ImmunoTherapeuticsSan Mateo, CA, US · est. 2004

Artielle ImmunoTherapeutics: A biotech firm innovating drugs for autoimmune diseases treatment.

Angel · $11.2M8
Atara BiotherapeuticsAtara BiotherapeuticsSouth San Francisco, CA, UST-Cell Therapiesest. 2012Atara BiotherapeuticsSouth San Francisco, CA, US · est. 2012

Atara Biotherapeutics: A clinical-stage biotech firm dedicated to developing therapies for severe diseases.

Public · $499.8M334
Arcutis BiotherapeuticsArcutis BiotherapeuticsWestlake Village, CA, USBiopharmaceuticalsest. 2016Arcutis BiotherapeuticsWestlake Village, CA, US · est. 2016

Founded in 2016, Arcutis is a clinical-stage biopharmaceutical company innovating in medical dermatology.

Public · $683.5M268
Artin BioscienceArtin BioscienceDenver, CO, USDrugs, Therapeuticsest. 2020Artin BioscienceDenver, CO, US · est. 2020

Artin Bioscience: Developing innovative therapies for respiratory diseases including COVID-19, ARDS, COPD, and PAH.

Seed · $482.5k6
Intarcia Therapeutics
Intarcia Therapeutics
Late Stage Private$1.7B3751995Hayward, CA, US
Board Member· Board

Leadership at Intarcia Therapeutics

Emad RizkEmad RizkBoard Member
David FranklinDavid FranklinCo-Founder
Bryan RobertsBryan RobertsBoard Member
Kurt GravesKurt GravesBoard Member
Jay SkylerJay SkylerBoard Member
Thomas AlessiThomas AlessiCo-Founder

Gino Santini's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Gino Santini

Christopher B WrightChristopher B WrightBoard Member · GP InvestmentsKen CarterKen CarterBoard Member · BioHealth InnovationTomer BigerTomer BigerFounder · NobleSunil SanghaviSunil SanghaviCEO · Noble.AIRichard ElmanRichard ElmanFounder · Noble GroupBill YoungBill YoungBoard Member · Intact Ventures